

16 December 2016

Our Ref: RFI 19039

Dear

**Freedom of Information Act 2000
Biologics and Biosimilar prescribing**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for the information relating to the above which you requested on 28 November 2016.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**L McAree (Miss)
Head of Information Governance &
Directorate Support**

Q1. *I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.*

A1. The table format you provided has been completed below with the figures from the Trust.

	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)	4	0	0
Adalimumab (Humira)	157	57	38
Apremilast (Otezla)	0	0	0
Certolizumab Pegol (Cimzia)	2	0	0
Etanercept (Enbrel)	157	7	0
Etanercept biosimilar (Benepali)	0	0	0
Golimumab (Simponi)	60	0	3
Infliximab (Remicade)	6	3	83
Infliximab biosimilar (Inflectra)	0	0	0
Infliximab biosimilar (Remsima)	0	0	49
Rituximab (MabThera)	86	0	0
Secukinumab (Cosentyx)	0	7	0
Ixekizumab (Taltz)	0	0	0
Tocilizumab (RoActemra)	18	0	0
Ustekinumab (Stelara)	6	34	0
Vedolizumab (Entyvio)	0	0	7